Pharsight

1. Invega Hafyera patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP16777058A	2021-01-22	df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB	Granted and Under Opposition
EP16777058A	2021-01-22	Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB	Granted and Under Opposition
EP16777058A	2021-01-22	STADA Arzneimittel AG	Granted and Under Opposition
EP16777058A	2021-01-21	Hexal AG	Granted and Under Opposition
EP16777058A	2021-01-21	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP16777058A	2021-01-21	Accord Healthcare Ltd	Granted and Under Opposition
EP16777058A	2021-01-19	Hamm&Wittkopp Patentanwälte PartmbB	Granted and Under Opposition
EP16777058A	2020-12-01	Instone, Terry/Read, Howard Graham/Appleyard Lees IP LLP	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143693	JANSSEN PHARMS	Dosing regimen for missed doses for long-acting injectable paliperidone esters	Apr, 2036 (12 years from now)
US11324751	JANSSEN PHARMS	Dosing regimens associated with extended release paliperidone injectable formulations	May, 2041 (17 years from now)
US11304951	JANSSEN PHARMS	Dosing regimens associated with extended release paliperidone injectable formulations	May, 2041 (17 years from now)
US11666697	JANSSEN PHARMS	Methods for ensuring resuspension of paliperidone palmitate formulations	Nov, 2041 (18 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Strength (NS)	Aug 30, 2024

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 18 May, 2015

Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago; Treatment of schizophrenia by ad...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Submission Date	ANDA(s) Filed	Last patent expiry
546 mg/1.75 mL	24 Jun, 2020	1	05 Apr, 2036
819 mg/2.625 mL	30 Apr, 2021	1	05 Apr, 2036
273 mg/0.875 mL and 410 mg/1.315 mL	14 Jul, 2021	1	05 Apr, 2036

Strength	Dosage	Availability
1.092GM/3.5ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
1.560GM/5ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
273MG/0.875ML (273MG/0.875ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
410MG/1.315ML (311.79MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
546MG/1.75ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
819MG/2.625ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

INVEGA HAFYERA family patents

2. Invega Sustenna patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP08863534A	2021-12-31	Zentiva k.s.	Granted and Under Opposition
EP08863534A	2021-12-31	EGIS Gyógyszergyár Zártkörüen Müködö Részvénytársaság	Granted and Under Opposition
EP08863534A	2021-12-30	Hoffmann Eitle SLU	Granted and Under Opposition
EP08863534A	2021-12-29	Gill Jennings & Every LLP	Granted and Under Opposition
EP08863534A	2021-12-29	Farmaprojects S.A.U.	Granted and Under Opposition
EP08863534A	2021-12-28	Laboratorios Lesvi, S.L.	Granted and Under Opposition
EP08863534A	2021-12-27	Sun Pharmaceutical Industries Europe B.V.	Granted and Under Opposition
EP08863534A	2021-12-27	Tolmar International Limited	Granted and Under Opposition
EP08863534A	2021-12-23	df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB	Granted and Under Opposition
EP08863534A	2021-12-23	BIOGARAN	Granted and Under Opposition
EP08863534A	2021-12-22	EVER Valinject GmbH	Granted and Under Opposition
EP08863534A	2021-12-22	Hoffmann Eitle	Granted and Under Opposition
EP08863534A	2021-12-22	Accord Healthcare Ltd	Granted and Under Opposition
EP08863534A	2021-12-20	Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi	Granted and Under Opposition
EP08863534A	2021-12-20	Maiwald Patent- und Rechtsanwaltsgesellschaft mbH	Granted and Under Opposition
EP08863534A	2021-12-20	Abbott Products Operations AG	Granted and Under Opposition
EP08863534A	2021-12-17	Stada-Arzneimittel Aktiengesellschaft	Granted and Under Opposition
EP08863534A	2021-12-10	Instone, Terry/Appleyard Lees IP LLP/Read, Howard	Granted and Under Opposition
EP08863534A	2021-12-03	Advanz Pharma Services (UK) Ltd.	Granted and Under Opposition
EP08863534A	2021-03-31	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9439906	February, 2020	Terminated-Denied	Janssen Pharmaceutica NV	Mylan Laboratories Ltd.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439906	JANSSEN PHARMS	Dosing regimen associated with long acting injectable paliperidone esters	Jan, 2031 (7 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: Treatment of schizophrenia; Treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; Dosing regimen for the treatment of schizoaffective disorde...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL and 234 mg/1.5 mL	21 Nov, 2017	1	06 Jul, 2021	26 Jan, 2031	Deferred

Strength	Dosage	Availability
39MG/0.25ML (39MG/0.25ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
78MG/0.5ML (78MG/0.5ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
117MG/0.75ML (117MG/0.75ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
156MG/ML (156MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
234MG/1.5ML (156MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

INVEGA SUSTENNA family patents

3. Invokamet patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP10735109A	2020-01-31	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP10735109A	2020-01-31	Generics [UK] Limited	Granted and Under Opposition
EP14194507A	2018-06-06	Galenicum Health S.L.	Patent maintained as amended
EP14194507A	2018-06-05	Generics (UK) Ltd	Patent maintained as amended
EP07850306A	2014-11-12	Galenicum Health S.L.	Patent maintained as amended
EP04771314A	2013-10-16	Galenicum Health S.L.	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2027 (3 years from now)
US8513202	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	Dec, 2027 (4 years from now)
US7943582	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	Feb, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2024 (10 months from now)
US8222219	JANSSEN PHARMS	Glucopyranoside compound	Apr, 2025 (1 year, 6 months from now)
US11576894	JANSSEN PHARMS	Combination therapy for the treatment of diabetes	Jul, 2030 (6 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2014

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
50 mg/500 mg 50 mg/1000 mg 150 mg/500 mg 150 mg/1000 mg	29 Mar, 2017	6		26 Feb, 2029

Strength	Dosage	Availability
50MG;500MG	TABLET;ORAL	Prescription
50MG;1GM	TABLET;ORAL	Prescription
150MG;500MG	TABLET;ORAL	Prescription
150MG;1GM	TABLET;ORAL	Prescription

INVOKAMET family patents

4. Invokamet Xr patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP14194507A	2018-06-06	Galenicum Health S.L.	Patent maintained as amended
EP14194507A	2018-06-05	Generics (UK) Ltd	Patent maintained as amended
EP07850306A	2014-11-12	Galenicum Health S.L.	Patent maintained as amended
EP04771314A	2013-10-16	Galenicum Health S.L.	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2027 (3 years from now)
US8513202	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	Dec, 2027 (4 years from now)
US7943582	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	Feb, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2024 (10 months from now)
US8222219	JANSSEN PHARMS	Glucopyranoside compound	Apr, 2025 (1 year, 6 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 20 September, 2016

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
50 mg/500 mg 50 mg/1000 mg 150 mg/500 mg 150 mg/1000 mg	21 Nov, 2018	1		26 Feb, 2029

Strength	Dosage	Availability
50MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
50MG;500MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
150MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
150MG;500MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

INVOKAMET XR family patents

5. Invokana patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP14194507A	2018-06-06	Galenicum Health S.L.	Patent maintained as amended
EP14194507A	2018-06-05	Generics (UK) Ltd	Patent maintained as amended
EP11721616A	2017-04-13	LEK Pharmaceuticals d.d.	Revoked
EP07850306A	2014-11-12	Galenicum Health S.L.	Patent maintained as amended
EP04771314A	2013-10-16	Galenicum Health S.L.	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2027 (3 years from now)
US8513202	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	Dec, 2027 (4 years from now)
US7943582	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	Feb, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219	JANSSEN PHARMS	Glucopyranoside compound	Apr, 2025 (1 year, 6 months from now)
US10617668	JANSSEN PHARMS	Pharmaceutical formulations	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication (I)	Sep 27, 2022

Drugs and Companies using CANAGLIFLOZIN ingredient

Market Authorisation Date: 29 March, 2013

Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, do...

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg and 300 mg	29 Mar, 2017	10		26 Feb, 2029

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Prescription

INVOKANA family patents

6. Levaquin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6806256	JANSSEN PHARMS	Taste masked liquid pharmaceutical compositions	Feb, 2022 (1 year, 7 months ago)
US6806256 (Pediatric)	JANSSEN PHARMS	Taste masked liquid pharmaceutical compositions	Aug, 2022 (1 year, 1 month ago)

Drugs and Companies using LEVOFLOXACIN ingredient

Market Authorisation Date: 21 October, 2004

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg/mL	30 Jul, 2009	1	20 Jun, 2011	26 Feb, 2022	Eligible

Strength	Dosage	Availability
250MG/10ML	SOLUTION;ORAL	Discontinued

LEVAQUIN family patents

7. Ponvory patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP15807916A	2022-10-26	STADA Arzneimittel AG	Granted and Under Opposition
EP15807916A	2022-10-21	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43728	JANSSEN PHARMS	Thiazolidin-4-one derivatives	Nov, 2024 (1 year, 1 month from now)
US9062014	JANSSEN PHARMS	Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one	May, 2032 (8 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018	JANSSEN PHARMS	Thiazolidin-4-one-derivatives	Nov, 2024 (1 year, 1 month from now)
US8273779	JANSSEN PHARMS	Thiazolidin 4-one derivatives	Dec, 2025 (2 years from now)
US10220023	JANSSEN PHARMS	Dosing regimen for a selective S1P1 receptor agonist	Dec, 2035 (12 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 2025-03-18

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
3MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
6MG	TABLET;ORAL	Prescription
7MG	TABLET;ORAL	Prescription
8MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription

PONVORY family patents

8. Spravato patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592207	JANSSEN PHARMS	Intranasal administration of ketamine to treat depression	Mar, 2027 (3 years from now)
US8785500	JANSSEN PHARMS	Intranasal administration of ketamine to treat depression	Mar, 2033 (9 years from now)
US11446260	JANSSEN PHARMS	Pharmaceutical composition of S-ketamine hydrochloride	Mar, 2034 (10 years from now)
US11173134	JANSSEN PHARMS	Methods for the treatment of depression	Sep, 2035 (11 years from now)
US10869844	JANSSEN PHARMS	Methods for the treatment of depression	Sep, 2035 (11 years from now)
US11311500	JANSSEN PHARMS	Methods for the treatment of depression	Sep, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
NCE* (NCE*)	Mar 5, 2024
New Indication (I)	Jul 31, 2023

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 March, 2019

Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally...

Dosage: SPRAY;NASAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
28 mg	06 Mar, 2023	3		10 Sep, 2035

Strength	Dosage	Availability
EQ 28MG BASE	SPRAY;NASAL	Prescription

SPRAVATO family patents

9. Xarelto patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP06706291A	2021-04-14	Krka, d.d., Novo mesto	Opposition rejected
EP06706291A	2021-03-19	Zentiva Group, a.s.	Opposition rejected
EP06706291A	2016-01-26	ABG Patentes, S.L.	Opposition rejected
EP06706291A	2016-01-22	Hexal AG	Opposition rejected
EP06706291A	2016-01-22	Galenicum Health S.L.	Opposition rejected
EP06706291A	2016-01-22	Stolmár, Matthias	Opposition rejected
EP06706291A	2016-01-22	Kraus & Weisert Patentanwälte PartGmbB	Opposition rejected
EP06706291A	2016-01-21	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Opposition rejected
EP06706291A	2016-01-21	Teva Pharmaceutical Industries Ltd.	Opposition rejected
EP06706291A	2016-01-21	STADA Arzneimittel AG	Opposition rejected
EP06706291A	2016-01-21	Generics [UK] Limited (trading as Mylan)	Opposition rejected
EP06706291A	2016-01-21	Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi	Opposition rejected
EP06706291A	2016-01-21	Wittkopp, Alexander	Opposition rejected
EP06706291A	2016-01-06	Actavis Group PTC ehf	Opposition rejected
EP06706291A	2015-07-22	Breuer, Markus	Opposition rejected
EP2006000431W	2012-01-20	Spanolux N.V.- DIV. Balterio	Opposition rejected
EP04797879A	2008-11-12	Ratiopharm GmbH	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10828310	September, 2022	Final Written Decision	Bayer Pharma AG et al.	Teva Pharmaceuticals USA, Inc
US10828310	September, 2022	Final Written Decision	Bayer Pharma AG et al.	InvaGen Pharmaceuticals, Inc. et al.
US10828310	February, 2022	Final Written Decision	Bayer Pharma AG et al.	Mylan Pharmaceuticals Inc. et al.
US9539218	May, 2018	Terminated-Denied	Bayer Intellectual Property GmbH	Mylan Pharmaceuticals Inc.
US7157456	October, 2016	Terminated-Dismissed	Bayer Intellectual Property GmbH	Mylan Pharmaceuticals Inc
US9539218	January, 2014	Decision	Frank Misselwitz et al

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157456	JANSSEN PHARMS	Substituted oxazolidinones and their use in the field of blood coagulation	Aug, 2024 (10 months from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415053	JANSSEN PHARMS	Solid, orally administrable pharmaceutical composition	Nov, 2024 (1 year, 1 month from now)
US7157456 (Pediatric)	JANSSEN PHARMS	Substituted oxazolidinones and their use in the field of blood coagulation	Feb, 2025 (1 year, 5 months from now)
US9415053 (Pediatric)	JANSSEN PHARMS	Solid, orally administrable pharmaceutical composition	May, 2025 (1 year, 7 months from now)
US9539218	JANSSEN PHARMS	Prevention and treatment of thromboembolic disorders	Feb, 2034 (10 years from now)
US9539218 (Pediatric)	JANSSEN PHARMS	Prevention and treatment of thromboembolic disorders	Aug, 2034 (10 years from now)
US10828310	JANSSEN PHARMS	Reducing the risk of cardiovascular events	Jan, 2039 (15 years from now)
US10828310 (Pediatric)	JANSSEN PHARMS	Reducing the risk of cardiovascular events	Jul, 2039 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication (I)	Aug 23, 2024
M (M)	Mar 10, 2023
Pediatric Exclusivity (PED)	Sep 10, 2023

Drugs and Companies using RIVAROXABAN ingredient

Market Authorisation Date: 01 July, 2011

Treatment: Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Treatment of deep vein thrombosis (dvt); Reduction of risk of major cardiovascular events (cv death, mi, and st...

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	Last patent expiry
2.5 mg	19 Nov, 2018	4	13 Nov, 2024
10 mg, 15 mg, and 20 mg	01 Jul, 2015	8	28 Aug, 2024
10 mg, 15 mg and 20 mg	17 Jun, 2022	1	17 Feb, 2034

Strength	Dosage	Availability
2.5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription

XARELTO family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Pharsight

Janssen Pharms patents expiration

1. Invega Hafyera patents expiration

INVEGA HAFYERA family patents

2. Invega Sustenna patents expiration

INVEGA SUSTENNA family patents

3. Invokamet patents expiration

INVOKAMET family patents

4. Invokamet Xr patents expiration

INVOKAMET XR family patents

5. Invokana patents expiration

INVOKANA family patents

6. Levaquin patents expiration

LEVAQUIN family patents

7. Ponvory patents expiration

PONVORY family patents

8. Spravato patents expiration

SPRAVATO family patents

9. Xarelto patents expiration

XARELTO family patents

Related content

Pharsight

Janssen Pharms patents expiration

1. Invega Hafyera patents expiration Share with your colleague

INVEGA HAFYERA family patents

2. Invega Sustenna patents expiration Share with your colleague

INVEGA SUSTENNA family patents

3. Invokamet patents expiration Share with your colleague

INVOKAMET family patents

4. Invokamet Xr patents expiration Share with your colleague

INVOKAMET XR family patents

5. Invokana patents expiration Share with your colleague

INVOKANA family patents

6. Levaquin patents expiration Share with your colleague

LEVAQUIN family patents

7. Ponvory patents expiration Share with your colleague

PONVORY family patents

8. Spravato patents expiration Share with your colleague

SPRAVATO family patents

9. Xarelto patents expiration Share with your colleague

XARELTO family patents

Related content

1. Invega Hafyera patents expiration

2. Invega Sustenna patents expiration

3. Invokamet patents expiration

4. Invokamet Xr patents expiration

5. Invokana patents expiration

6. Levaquin patents expiration

7. Ponvory patents expiration

8. Spravato patents expiration

9. Xarelto patents expiration